Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 2, 2008, Pages 324-331

  Rudolph, Volker ^a,b   Rudolph, Tanja K ^a,b   Schopfer, Francisco J ^b   Bonacci, Gustavo ^b   Lau, Denise ^a   Szöcs, Katalin ^a   Klinke, Anna ^a   Meinertz, Thomas ^a   Freeman, Bruce A ^b   Baldus, Stephan ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE; HEPARIN; HIRULOG; MYELOPEROXIDASE; NITRIC OXIDE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; ENDOTHELIUM CELL; FEMALE; HUMAN; IN VITRO STUDY; ISCHEMIA; MALE; METHYLATION; OXIDATION REDUCTION REACTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANIMALS; ANTITHROMBINS; BIOLOGICAL AVAILABILITY; CATTLE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HIRUDINS; HUMANS; MALE; METHYLATION; MIDDLE AGED; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEROXIDASE; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TYROSINE; VASODILATION;

EID: 54349093548     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142414     Document Type: Article

References (31)

1. Baldus S, Eiserich JP, Brennan ML, Jackson RM, Alexander CB, and Freeman BA (2002) Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 33:1010.
2. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, et al. (2001) Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 108:1759-1770.
3. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, and Hamm CW (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440-1445.
4. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, Sydow K, Lau D, Szöcs K, Klinke A, et al. (2006) Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113:1871-1878.
5. Bates SM and Weitz JI (2000) The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12 (Suppl F):27F-32F.
6. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, et al. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604.
7. Carr AC, McCall MR, and Frei B (2000) Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20:1716-1723.
8. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257-265.
9. Daphna EM, Michaela S, Eynat P, Irit A, and Rimon S (1998) Association of myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Mol Cell Biochem 183:55-61.
10. Eikelboom J, White H, and Yusuf S (2003) The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 41:70S-78S.
11. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, et al. (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391-2394.
12. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, and van der Vliet A (1998) Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397.
13. Fu X, Kassim SY, Parks WC, and Heinecke JW (2001) Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276:41279-41287.
14. Harding SA, Din JN, Sarma J, Josephs DH, Fox KA, and Newby DE (2006) Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 92:1635-1638.
15. Heinecke JW (1997) Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 6:145-155.
16. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Böger R, and Baldus S (2006) Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 26:1648-1652.
17. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, and Schmieder RE (1998) Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 98:211-216.
18. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, and Schneider DJ (2006) Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 118:361-369.
19. Laufs U, La Fata V, Plutzky J, and Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135.
20. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, et al. (2004) Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc 292:696-703.
21. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94:258-265.
22. Rudolph V, Rudolph TK, Hennings JC, Blankenberg S, Schnabel R, Steven D, Haddad M, Knittel K, Wende S, Wenzel J, et al. (2007a) Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med 43:1189-1196.
23. Rudolph V, Steven D, Gehling UM, Goldmann B, Rudolph TK, Friedrichs K, Meinertz T, Heitzer T, and Baldus S (2007b) Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease. Free Radic Biol Med 42:460-465.
24. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, et al. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113:156-175.
25. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, et al. (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J Am Med Assoc 298:2497-2506.
26. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, et al. (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-2230.
27. Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, and Luscher TF (2006) Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 47 (Suppl 2):S136-S150.
28. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, and Ferrari R (2003) Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 420:255-261.
29. Warkentin TE (2004) Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 17:105-125.
30. Weitz JI and Buller HR (2002) Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105:1004-1011.
31. Weitz JI and Crowther M (2002) Direct thrombin inhibitors. Thromb Res 106:V275-V284.